A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Triple Negative Breast Cancer|Hodgkin Lymphoma|Head and Neck Squamous Cell Carcinoma|Malignant Melanoma
Interventions: DRUG: CTX-8371
Sponsor: Compass Therapeutics